{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:31Z","timestamp":1791410791249,"version":"4.3.3"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T00:00:00Z","timestamp":1381276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.radonc.2013.08.030","type":"journal-article","created":{"date-parts":[[2013,9,20]],"date-time":"2013-09-20T16:16:35Z","timestamp":1379693795000},"page":"217-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":409,"title":["Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials"],"prefix":"10.1016","volume":"109","author":[{"given":"Christopher R.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bolzicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kupelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2013.08.030_b0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0090-4295(90)80207-4","article-title":"Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years\u2019 experience (1962\u20131984)","volume":"36","author":"Lloyd-Davies","year":"1990","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2013.08.030_b0010","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ijrobp.2007.01.067","article-title":"Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: Cleveland Clinic experience","volume":"68","author":"Kupelian","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0015","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial","volume":"81","author":"Yeoh","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0020","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijrobp.2009.12.045","article-title":"Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer","volume":"79","author":"Arcangeli","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0025","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","article-title":"Randomized trial comparing two fractionation schedules for patients with localized prostate cancer","volume":"23","author":"Lukka","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2013.08.030_b0030","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0360-3016(03)00752-1","article-title":"Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis","volume":"57","author":"Livsey","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0035","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2010.04.054","article-title":"A phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer","volume":"80","author":"Lock","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0040","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2007.04.049","article-title":"Phase II trial of hypofractionated image-guided intensity modulated radiotherapy for localized prostate adenocarcinoma","volume":"69","author":"Martin","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial","volume":"13","author":"Dearnaley","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2013.08.030_b0050","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.ijrobp.2008.09.032","article-title":"Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity","volume":"74","author":"Coote","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0055","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized prostate disease: first clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0060","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0065","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ijrobp.2007.11.067","article-title":"Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations","volume":"70","author":"Fuller","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2013.08.030_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2490-10-1","article-title":"Stereotactic body radiotherapy for organ-confined prostate cancer","volume":"10","author":"Katz","year":"2010","journal-title":"BMC Urol"},{"key":"10.1016\/j.radonc.2013.08.030_b0075","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2013.08.030_b0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/153303461000900505","article-title":"Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results","volume":"9","author":"Bolzicco","year":"2010","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.radonc.2013.08.030_b0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/153303460900800509","article-title":"Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer","volume":"8","author":"Friedland","year":"2009","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.radonc.2013.08.030_b0090","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2013.08.030_b0095","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited \u2013 an analysis of clinical results from 14,168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2013.08.030_b0100","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1464-410X.2010.09290.x","article-title":"The \u2018CaP Calculator\u2019: an online decision support tool for clinically localized prostate cancer","volume":"105","author":"Katz","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2013.08.030_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health related quality of life after stereotactic body radiotherapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814013004301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814013004301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T17:52:22Z","timestamp":1539366742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814013004301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0167814013004301"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2013.08.030","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2013.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}